Form 4: Ligand Pharmaceuticals CFO Octavio Espinoza Reports Stock Sales
SEC Form 4 Filing
Octavio Espinoza, CFO of Ligand Pharmaceuticals, reported the sale of common stock on September 20, 2024, according to a Form 4 filing with the SEC.
Summary
- Octavio Espinoza, the Chief Financial Officer of Ligand Pharmaceuticals, filed a Form 4 with the SEC.
- The filing reports the sale of Ligand Pharmaceuticals common stock on September 20, 2024.
- Mr. Espinoza sold 200 shares at $103.98, 275 shares at $103.8625, and 800 shares at $103.95.
- Following these transactions, Mr. Espinoza directly owns 24,610 shares of Ligand Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock sales by a company insider. It doesn't inherently convey positive or negative sentiment, but insider sales can sometimes be interpreted negatively by investors.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- Shareholders may react to the news of insider selling, potentially impacting the stock price.
Key Dates
| Date | Description |
|---|---|
| 09/20/2024 | Date of stock sale transactions |
| 09/24/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.